Acquisition Completed
Incyte acquisition of Vega Therapeutics
US$1.3bn consideration
Announced 8 Jun 2026
Advisers
Other advisers
- Financial adviser
- Target
- Vega Therapeutics
- Acquirer
- Incyte
- Seller
- Star Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Seller based in
- United States
- Completed
- 6 Jul 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Rare Disease
In the league tables
- M&A financial advisers, 2026 to date Evercore #4 · Morgan Stanley #6 · Lazard #11
- M&A financial advisers, completed, 2026 to date Evercore #4 · Morgan Stanley #6 · Lazard #14
- M&A legal advisers, 2026 to date Goodwin #12 · Fenwick & West #66
- M&A legal advisers, completed, 2026 to date Goodwin #17 · Fenwick & West #52
Similar deals
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
Sources
- 8 Jun 2026 Press release (EX-99.1, exhibit), Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders sec.gov
- 8 Jun 2026 Evercore: Advised Star Therapeutics on the sale of its subsidiary, Vega Therapeutics, to Incyte evercore.com
- 12 Jun 2026 Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders goodwinlaw.com
- 6 Jul 2026 Press release (EX-99.1, exhibit), Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio sec.gov
- 6 Jul 2026 Lazard: UNITED STATES Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders lazard.com



